A Drug Interaction Study Investigating the Effect of Rifabutin on the Pharmacokinetics of Maraviroc (RIFAMARA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

Healthy volunteers are being recruited for this pharmacokinetics study. The objective is to characterize the pharmacokinetic properties of maraviroc alone and when administered with rifabutin and to assess rifabutin and 25-O-desacetyl-rifabutin pharmacokinetics compared to the literature.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

18 Years to 65 Years (Adult)

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Criteria

Inclusion Criteria:

Able and willing to sign informed consent prior to any study-related activities.

Willing to stop using any herbal or natural health products for 2 weeks prior to and during the study including: Grapefruit, grapefruit juice, St. John's Wort.

Willingness to abstain from alcohol use for 3 days prior to and during the study.

Participant must practice a reliable method of birth control while they are participating in the study; for instance an intrauterine device (IUD), condom with spermicidal gel or foam, diaphragm with spermicidal gel or foam, vasectomy, tubal ligation, hysterectomy or abstinence or female must be post menopausal for at least one year.

Exclusion Criteria:

Have serological evidence of exposure to HIV

Female patients of childbearing potential who has a positive urine pregnancy test at screening

Participants not willing to use a reliable method of barrier contraception during the study.

Is breastfeeding.

Inability to adhere to protocol.

Use of any medications (2 weeks prior to or during the study) other than occasional use of acetaminophen.

Participants taking oral contraceptive medications.

Any condition possibly affecting drug absorption (eg, gastrectomy).

Patients may be excluded from the study for other reasons, at the investigator's discretion.